WallStSmart

Southern Copper Corporation (SCCO)vsVersamet Royalties Corporation Common Stock (VMET)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Southern Copper Corporation generates 22960% more annual revenue ($17.11B vs $74.18M). VMET leads profitability with a 49.9% profit margin vs 37.2%. SCCO trades at a lower P/E of 23.6x. SCCO earns a higher WallStSmart Score of 65/100 (B-).

SCCO

Strong Buy

65

out of 100

Grade: B-

Growth: 9.3Profit: 10.0Value: 3.3Quality: 8.0
Piotroski: 5/9Altman Z: 3.11

VMET

Buy

60

out of 100

Grade: C+

Growth: 10.0Profit: 8.0Value: 5.3Quality: 4.5
Piotroski: 5/9Altman Z: 1.19
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

SCCOSignificantly Overvalued (-79.2%)

Margin of Safety

-79.2%

Fair Value

$117.56

Current Price

$167.27

$49.71 premium

UndervaluedFair: $117.56Overvalued

Intrinsic value data unavailable for VMET.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

SCCO6 strengths · Avg: 10.0/10
Return on EquityProfitability
47.1%10/10

Every $100 of equity generates 47 in profit

Profit MarginProfitability
37.2%10/10

Keeps 37 of every $100 in revenue as profit

Operating MarginProfitability
59.9%10/10

Strong operational efficiency at 59.9%

Revenue GrowthGrowth
39.1%10/10

Revenue surging 39.1% year-over-year

EPS GrowthGrowth
66.0%10/10

Earnings expanding 66.0% YoY

Altman Z-ScoreHealth
3.1110/10

Safe zone — low bankruptcy risk

VMET5 strengths · Avg: 9.6/10
Profit MarginProfitability
49.9%10/10

Keeps 50 of every $100 in revenue as profit

Operating MarginProfitability
58.0%10/10

Strong operational efficiency at 58.0%

Revenue GrowthGrowth
391.9%10/10

Revenue surging 391.9% year-over-year

EPS GrowthGrowth
2123.0%10/10

Earnings expanding 2123.0% YoY

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Areas to Watch

SCCO2 concerns · Avg: 3.0/10
Price/BookValuation
10.4x4/10

Trading at 10.4x book value

PEG RatioValuation
5.412/10

Expensive relative to growth rate

VMET2 concerns · Avg: 2.5/10
Market CapQuality
$926.14M3/10

Smaller company, higher risk/reward

Altman Z-ScoreHealth
1.192/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : SCCO

The strongest argument for SCCO centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 37.2% and operating margin at 59.9%. Revenue growth of 39.1% demonstrates continued momentum.

Bull Case : VMET

The strongest argument for VMET centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 49.9% and operating margin at 58.0%. Revenue growth of 391.9% demonstrates continued momentum.

Bear Case : SCCO

The primary concerns for SCCO are Price/Book, PEG Ratio.

Bear Case : VMET

The primary concerns for VMET are Market Cap, Altman Z-Score.

Key Dynamics to Monitor

VMET is growing revenue faster at 391.9% — sustainability is the question.

SCCO generates stronger free cash flow (1.7B), providing more financial flexibility.

Monitor COPPER industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SCCO scores higher overall (65/100 vs 60/100), backed by strong 37.2% margins and 39.1% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Southern Copper Corporation

BASIC MATERIALS · COPPER · USA

Southern Copper Corporation is engaged in the extraction, exploration, smelting and refining of copper and other minerals in Peru, Mexico, Argentina, Ecuador and Chile.

Visit Website →

Versamet Royalties Corporation Common Stock

BASIC MATERIALS · OTHER PRECIOUS METALS & MINING · USA

Viamet Pharmaceuticals Corp (VMET) is an innovative biopharmaceutical company dedicated to the development of advanced therapeutics targeting serious diseases, particularly in the areas of fungal infections and oncology, utilizing its proprietary metalloenzyme-based technology platform. With a robust and diversified clinical pipeline supported by strategic partnerships and a comprehensive intellectual property portfolio, Viamet is strategically positioned for significant growth. The company remains focused on addressing critical unmet medical needs and is committed to enhancing shareholder value through continued therapeutic advancements in its specialized areas.

Want to dig deeper into these stocks?